Been digging into some of the genetics sector moves from the past couple years and honestly, the momentum in gene therapy stocks has been pretty wild to watch. The whole genetic testing stocks space has matured significantly, especially with companies actually getting FDA approvals for therapies that seemed impossible just a few years back.

The genetics market itself is massive - we're talking an estimated US$8.98 billion back in 2024, projected to hit US$57.13 billion by 2034. That's an 18.52% compound annual growth rate, which explains why so many biotech firms are pouring resources into this area.

Let me run through some of the standouts that caught attention. Avidity Biosciences (RNA) was one of the bigger movers - their antibody oligonucleotide conjugate platform for rare muscle diseases showed some serious potential. They hit FDA breakthrough therapy status for myotonic dystrophy, and when they dropped that positive Phase 1/2 data showing over 50% reductions in certain gene markers, the stock absolutely flew. Peaked around US$52.50 by November 2024.

Wave Life Sciences (WVE) was another interesting play - they're working on RNA-based medicines and actually demonstrated what they called the first-ever therapeutic RNA editing in humans. That kind of milestone tends to get the market's attention. Stock jumped hard on that news, hitting highs around US$16.44.

UniQure (QURE) has probably the most tangible win here - they actually got the world's first gene therapy for hemophilia B approved back in November 2022. That's not theoretical anymore, that's a marketed drug. They've been pushing forward with Huntington's disease therapies and secured an accelerated approval pathway with the FDA, which is a big deal.

Sangamo Therapeutics (SGMO) had some ups and downs - positive Phase 3 data for hemophilia A treatment, but then took a hit when Pfizer decided to exit their collaboration at the end of 2024. That's the kind of volatility you see in biotech when partnerships shift.

Stoke Therapeutics (STOK) is focused on RNA medicine for genetic epilepsy, got breakthrough designation for their Dravet syndrome candidate. That's another example of genetic testing stocks and gene therapy companies actually moving the needle on real medical problems.

The whole sector feels like it's transitioning from 'promising research' to 'actual approved therapies,' which changes the risk profile significantly. Worth keeping an eye on if you're tracking biotech or genetic medicine plays.